Literature DB >> 25278394

Vancomycin-resistant Enterococcus colonization in the intensive care unit: clinical outcomes and attributable costs of hospitalization.

Euihan Jung1, Sookjin Byun2, Hojin Lee1, Sang Yi Moon1, Hyuck Lee3.   

Abstract

BACKGROUND: The clinical and economic impact of vancomycin-resistant Enterococcus (VRE) colonization remains unclear. Little data are available on factors affecting hospitalization length of stay (LOS) and costs. This study aimed to estimate mortality, LOS, and hospitalization costs for VRE colonized patients compared with a matched hospital population.
METHODS: We performed a retrospective propensity score matched cohort study comparing the outcomes of patients with VRE colonization with those of uncolonized subjects matched at the time they were admitted to the intensive care unit (ICU). Between January 2008 and December 2010, we obtained rectal swab cultures within 24 hours of ICU admission to detect VRE colonization.
RESULTS: During the study period, 567 (7.2%) of the 7,703 patients were colonized with VRE. There were 199 VRE colonized patients compared with 199 uncolonized patients using the propensity score. VRE colonized patients when compared with uncolonized patients were likely to have a higher case fatality rate (24.6% vs 17.1%; OR, 2.35). Longer total admission days were observed in the VRE colonized patients (28.7 vs 21.4 days; multiplicative effect, 1.25; P = .004). VRE colonization is found to be a significant factor associated with increased ICU cost in the multivariable regression model ($6,065 vs $5,298; multiplicative effect, 1.22; P = .029). Multivariable analysis identified the factors affecting ICU cost as follows: VRE colonization (odds ratio [OR], 1.20; P = .038), ICU length of stay (OR, 1.93; P < .001), ICU type (OR, 1.51; P = .001), valvular heart disease (OR, 2.38; P = .27), hospitalization within 12 months (OR, 1.21; P = .037), and use of invasive devices (OR, 1.28; P = .017).
CONCLUSION: Compared with a matched hospital population, VRE colonization was associated with increased mortality, LOS, and costs. Strict infection control programs, including preemptive isolation for a high-risk group, should be helpful.
Copyright © 2014 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enterococcus; Infection control; Intensive care units; Vancomycin resistance

Mesh:

Year:  2014        PMID: 25278394     DOI: 10.1016/j.ajic.2014.06.024

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  18 in total

1.  Co-colonization by multidrug-resistant bacteria in two Greek intensive care units.

Authors:  M Papadimitriou-Olivgeris; I Spiliopoulou; M Christofidou; D Logothetis; P Manolopoulou; V Dodou; F Fligou; M Marangos; E D Anastassiou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-15       Impact factor: 3.267

2.  Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection.

Authors:  Daniel E Freedberg; Margaret J Zhou; Margot E Cohen; Medini K Annavajhala; Sabrina Khan; Dagmara I Moscoso; Christian Brooks; Susan Whittier; David H Chong; Anne-Catrin Uhlemann; Julian A Abrams
Journal:  Intensive Care Med       Date:  2018-06-23       Impact factor: 17.440

3.  The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms.

Authors:  Srinivasa Nithin Gopalsamy; Michael H Woodworth; Tiffany Wang; Cynthia T Carpentieri; Nirja Mehta; Rachel J Friedman-Moraco; Aneesh K Mehta; Christian P Larsen; Colleen S Kraft
Journal:  Am J Med Sci       Date:  2018-08-29       Impact factor: 2.378

4.  Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection.

Authors:  Erik R Dubberke; Kathleen M Mullane; Dale N Gerding; Christine H Lee; Thomas J Louie; Harriet Guthertz; Courtney Jones
Journal:  Open Forum Infect Dis       Date:  2016-06-20       Impact factor: 3.835

5.  Economic burden of nosocomial infections caused by vancomycin-resistant enterococci.

Authors:  Laura Puchter; Iris Freya Chaberny; Frank Schwab; Ralf-Peter Vonberg; Franz-Christoph Bange; Ella Ebadi
Journal:  Antimicrob Resist Infect Control       Date:  2018-01-05       Impact factor: 4.887

6.  A new approach to Vancomycin utilization evaluation: A cross-sectional study in intensive care unit.

Authors:  Atefeh Mahmoodian; Saeed Abbasi; Shadi Farsaei
Journal:  J Res Pharm Pract       Date:  2016 Oct-Dec

7.  Genomic surveillance of antimicrobial resistant bacterial colonisation and infection in intensive care patients.

Authors:  Kelly L Wyres; Jane Hawkey; Mirianne Mirčeta; Louise M Judd; Ryan R Wick; Claire L Gorrie; Nigel F Pratt; Jill S Garlick; Kerrie M Watson; David V Pilcher; Steve A McGloughlin; Iain J Abbott; Nenad Macesic; Denis W Spelman; Adam W J Jenney; Kathryn E Holt
Journal:  BMC Infect Dis       Date:  2021-07-14       Impact factor: 3.090

8.  Clinical and Economic Evaluation of Multidrug-Resistant Acinetobacter baumannii Colonization in the Intensive Care Unit.

Authors:  Hojin Lee; Hyuck Lee
Journal:  Infect Chemother       Date:  2016-09-19

9.  Antibiotic-Induced Pathobiont Dissemination Accelerates Mortality in Severe Experimental Pancreatitis.

Authors:  Fernanda S Soares; Flávia C Amaral; Natália L C Silva; Matheus R Valente; Lorena K R Santos; Lívia H Yamashiro; Mara C Scheffer; Fernanda V E S Castanheira; Raphael G Ferreira; Laura Gehrke; José C Alves-Filho; Luciano P Silva; André Báfica; Fernando Spiller
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

10.  In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital.

Authors:  Sabine Engler-Hüsch; Thomas Heister; Nico T Mutters; Jan Wolff; Klaus Kaier
Journal:  BMC Health Serv Res       Date:  2018-09-26       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.